The SURMOUNT-1 trial showed 22.5% average weight loss with tirzepatide at 15 mg, compared to 14.9% with semaglutide at 2.4 mg in the STEP-1 trial
Individuals with melasma, hyperpigmentation, or sun damage People recovering from travel, photoaging, or environmental exposure Patients pairing with microneedling, peels, or skin laser treatments Anyone wanting to brighten and even skin tone naturally Patients seeking antioxidant support during detox or skin inflammation High-stress professionals with visible skin fatigue In preparation for cosmetic procedures Interested in NAD+ or anti-aging stacking later Built for Skin Brightening: Specifically designed for pigmentation concerns like melasma, age spots, and post-acne marks
According to the MHRA/EMC Summary of Product Characteristics, these include: Very common (may affect more than 1 in 10 people): Nausea Diarrhoea Common (may affect up to 1 in 10 people): Vomiting Abdominal pain Constipation Dyspepsia (indigestion) Decreased appetite These symptoms typically diminish over time as the body adjusts to the medication
BPC-157 is not a drug, not a dietary supplement, not a cosmetic, and not approved by the FDA, EMA, or any other regulatory authority for use in humans or animals
Microdermabrasion Procedure Microdermabrasion, often called a lunch hour treatment for its quick nature, lasting around 50 minutes, and not even requiring anesthesia or any other numbing agent
serious adverse effects such as pancreatitis require immediate medical attention
